SE
semaglutide (Ozempic / Wegovy / Novotel)
Novo Nordisk A/S Ā· GLP1R Ā· Small Molecule
Status
ā Approved
Indications
9 conditions
Clinical Trials
552 total
Active Trials
257 ongoing
Targets
GLP1R
What is semaglutide?
Last updated: February 2025semaglutide is a small molecule developed by Novo Nordisk A/S. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.
Drug Profile
| Generic Name | semaglutide |
| Brand Names | Ozempic, Wegovy, Novotel |
| Company | Novo Nordisk A/S |
| Drug Class | Small Molecule, Recombinant Proteins, Polypeptide |
| Molecular Target | GLP1R |
| Route | Injectable (Others), Subcutaneous Injection |
| Status | Approved |
Sources: ClinicalTrials.gov, Novo Nordisk A/S
Mechanism of Action
Molecular Targets
semaglutide acts on 1 molecular target:
| GLP1R | glucagon like peptide 1 receptor (GLP-1R, GLP-1-R) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Clinical Trials
There are currently 552 clinical trials registered, with 257 actively ongoing.
| Trial ID | Phase | Title | Status |
|---|---|---|---|
| NCT06478550 | N/A | A Pilot Study Investigating the Effect of Patient Support Solution App With Connectivity on Once-wee | Completed |
| NCT07294950 | Phase 3 | Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: a Rand | ā Recruiting |
| NCT07389941 | Phase 4 | Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF) | ā Not Yet Recruiting |
| NCT07401992 | Phase 4 | Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis: A Randomized, T | ā Recruiting |
| NCT07172867 | Phase 2 | A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study to Evaluate the Safety, Eff | ā Recruiting |
| NCT06608433 | NA | Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function - the PIANO Study | Completed |
+548 more trials available with free account
Sign up free to view all clinical trials āAnalyze Full Trial DataNoah can compare efficacy across trials and generate reports.
Therapeutic Indications
semaglutide is developed for 9 unique indications across 7 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Metabolism and nutrition disorders | Obesity | ā Approved |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | ā Approved |
| Cardiac disorders | Cardiac failure | ā Approved |
| Nervous system disorders | Dementia Alzheimer's type | ā Approved |
| Hepatobiliary disorders | Metabolic dysfunction-associated steatohepatitis | ā Approved |
+4 more indications available with free account
Sign up free to view all indications ā